Skip to main content

Overall Survival Not Extended With Bevacizumab and Erlotinib in EGFR-Mutant NSCLC

*March 2022*

Adding bevacizumab to the use of erlotinib (Tarceva) in patients with EGFR-mutated non–small cell lung cancer (NSCLC) did not prolong their survival. However, both treatment arms with and without bevacizumab (Avastin) had relatively long survival durations that encouraged researchers, according to study results published in the LancetRead more.